Business
AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics
AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"\n \n \n \n AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n - Strategic alliance will accelerate global development of broad spectrum antiviral oral medicine Avigan®/Reeqonus™ (favipiravir) for the treatment of COVID-19 and other infectious diseases\n \n \n - Worldwide sales of Avigan®/Reeqonus™ (favipiravir) have reached $190,000,000 in 2021, with more than 1.5M COVID-19 patients treated to date\n \n \n - Stock swap aligns both companies more closely, demonstrating their shared interest in increasing sales of Avigan®/Reeqonus (favipiravir) worldwide and to further develop both organization's pipelines\n \n \n - Appili has a promising pipeline of specialty therapeutics\n \n \n - AiPharma's sales of Avigan/Reeqonus provide cashflow for today and future investments\n \n \n - Strategic alliance will enable the companies to align additional resources, partners and assets with the objective of evolving into a global integrated infectious disease healthcare company\n \n \n PR Newswire\n \n \n \n \n \n DUBLIN\n \n ,\n \n Sept. 29, 2021\n \n /PRNewswire/ -- AiPharma Global Holdings LLC (\n \n \"\n \n \n AiPharma\n \n \"), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (\n \n \"\n \n \n Appili\n \n \"), a biopharmaceutical company focused on drug development for infectious diseases, announced today a strategic alliance to advance the global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral currently being evaluated by Appili for the potential treatment and prevention of COVID-19. AiPharma and Appili entered into a strategic alliance agreement (the\n \n \"\n \n \n Definitive Agreement\n \n \") to establish minority positions in each other's businesses, further align their goals, and participate in each other's respective economic interests.\n \n \n Avigan®/Reeqonus™ (favipiravir) is a broad-spectrum anti-v...